In a new setback, Seres cites Covid impact after deciding to shelve its lead microbiome cancer program
Seven months after a big, come-from-behind win in Phase III for its lead microbiome program, Seres has another setback to report — this time on the cancer front.
The biotech $MCRB says that its partnered program with the Parker Institute for Cancer Immunotherapy in metastatic melanoma is being shelved, citing “challenges” presented by running the study during the pandemic. Word is that they came to the decision to sideline the effort after 10 patients received a combination of SER-401 with Opdivo, Bristol Myers’ big PD-1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.